rivastigmine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
acetylcholinesterase inhibitors 2392 123441-03-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prometax
  • rivastigmine
  • S-Rivastigmine
  • rivastigmine tartrate
  • rivastigmine hydrogen tartrate
  • rivastigmine hexal
  • exelon
A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.
  • Molecular weight: 250.34
  • Formula: C14H22N2O2
  • CLOGP: 2.10
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 32.78
  • ALOGS: -2.09
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
9 mg O
9.50 mg TD

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.80 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 72 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.60 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 12, 1998 EMA
April 21, 2000 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product adhesion issue 420.23 17.01 128 16813 4827 46664294
Application site erythema 349.92 17.01 111 16830 4793 46664328
Dementia 279.48 17.01 127 16814 14803 46654318
Hallucination 275.44 17.01 190 16751 49761 46619360
Application site pruritus 258.28 17.01 84 16857 3929 46665192
Fall 241.90 17.01 429 16512 328668 46340453
Confusional state 184.69 17.01 257 16684 159635 46509486
Death 184.38 17.01 387 16554 335161 46333960
Application site rash 153.86 17.01 51 16890 2531 46666590
Agitation 146.39 17.01 137 16804 55278 46613843
Disorientation 118.69 17.01 102 16839 36816 46632305
Aggression 114.70 17.01 82 16859 22662 46646459
Hallucination, visual 112.77 17.01 74 16867 17799 46651322
Application site hypersensitivity 112.39 17.01 24 16917 202 46668919
Cognitive disorder 100.86 17.01 93 16848 36790 46632331
Abnormal behaviour 99.52 17.01 73 16868 20985 46648136
Blood cholinesterase decreased 92.44 17.01 19 16922 130 46668991
Memory impairment 88.58 17.01 124 16817 77213 46591908
Wrong technique in product usage process 85.42 17.01 102 16839 54320 46614801
Bradycardia 78.45 17.01 108 16833 66190 46602931
Delusion 77.16 17.01 49 16892 11139 46657982
Application site reaction 75.24 17.01 22 16919 717 46668404
Product administration error 74.93 17.01 60 16881 19621 46649500
Rheumatoid arthritis 74.27 17.01 3 16938 240212 46428909
Mini mental status examination abnormal 73.49 17.01 11 16930 3 46669118
Arthralgia 71.20 17.01 22 16919 364581 46304540
Application site irritation 70.19 17.01 26 16915 1793 46667328
Dementia Alzheimer's type 68.78 17.01 23 16918 1172 46667949
Lack of application site rotation 66.60 17.01 10 16931 3 46669118
Cerebral atrophy 63.45 17.01 32 16909 4684 46664437
Syncope 59.62 17.01 123 16818 104680 46564441
Skin irritation 58.08 17.01 35 16906 7252 46661869
Restlessness 57.74 17.01 58 16883 25466 46643655
On and off phenomenon 57.33 17.01 23 16918 1968 46667153
Vomiting 57.00 17.01 318 16623 452476 46216645
Bradykinesia 56.57 17.01 28 16913 3938 46665183
Cholinergic syndrome 55.37 17.01 15 16926 368 46668753
Dyskinesia 55.17 17.01 60 16881 28865 46640256
Drug hypersensitivity 54.72 17.01 11 16930 243814 46425307
Femur fracture 54.22 17.01 67 16874 36930 46632191
Product administration interrupted 54.21 17.01 15 16926 399 46668722
Dysphagia 54.04 17.01 99 16842 77213 46591908
Pneumonia aspiration 52.49 17.01 61 16880 31544 46637577
Stoma site discharge 51.02 17.01 21 16920 1919 46667202
Delirium 50.71 17.01 65 16876 37163 46631958
Speech disorder 50.61 17.01 64 16877 36103 46633018
Loss of consciousness 50.17 17.01 117 16824 108121 46561000
Akinesia 49.09 17.01 20 16921 1781 46667340
General physical health deterioration 48.14 17.01 120 16821 115649 46553472
Marasmus 47.62 17.01 14 16927 465 46668656
Pain 46.77 17.01 63 16878 476885 46192236
Cerebrovascular accident 46.58 17.01 109 16832 100930 46568191
Dementia with Lewy bodies 46.11 17.01 12 16929 251 46668870
Gait inability 44.11 17.01 59 16882 35144 46633977
Malaise 43.15 17.01 235 16706 330997 46338124
Tremor 41.05 17.01 113 16828 115526 46553595
Decreased appetite 40.43 17.01 158 16783 193678 46475443
Freezing phenomenon 38.88 17.01 16 16925 1461 46667660
Somnolence 38.86 17.01 135 16806 156386 46512735
Completed suicide 38.69 17.01 4 16937 145916 46523205
Alopecia 37.10 17.01 7 16934 162407 46506714
Application site discolouration 36.81 17.01 13 16928 781 46668340
Subileus 36.41 17.01 19 16922 2984 46666137
Eating disorder 36.30 17.01 35 16906 14619 46654502
Dysstasia 36.06 17.01 38 16903 17630 46651491
Dyspnoea 33.77 17.01 87 16854 515461 46153660
Application site dermatitis 33.73 17.01 9 16932 208 46668913
Femoral neck fracture 33.63 17.01 26 16915 8077 46661044
Gait disturbance 33.23 17.01 122 16819 145141 46523980
Application site swelling 32.88 17.01 11 16930 561 46668560
Concomitant disease aggravated 32.08 17.01 25 16916 7857 46661264
Stoma site erythema 32.00 17.01 13 16928 1149 46667972
Pleurothotonus 31.97 17.01 13 16928 1152 46667969
Vascular encephalopathy 31.85 17.01 10 16931 416 46668705
Accessory cardiac pathway 31.67 17.01 5 16936 4 46669117
Muscle rigidity 30.92 17.01 27 16914 9934 46659187
Fatigue 30.50 17.01 116 16825 608581 46060540
Orthostatic hypotension 30.39 17.01 41 16900 24617 46644504
Extrapyramidal disorder 29.98 17.01 28 16913 11240 46657881
Pain in extremity 29.77 17.01 30 16911 258650 46410471
Fracture 29.38 17.01 33 16908 16438 46652683
Joint swelling 28.97 17.01 12 16929 166061 46503060
Sinusitis 28.78 17.01 6 16935 129762 46539359
Hypokinesia 27.96 17.01 27 16914 11295 46657826
Dehydration 27.71 17.01 123 16818 159417 46509704
Screaming 27.18 17.01 16 16925 3175 46665946
Back pain 26.97 17.01 22 16919 210017 46459104
Posture abnormal 26.96 17.01 14 16927 2176 46666945
Arrhythmia 26.09 17.01 46 16895 34795 46634326
Aphasia 25.77 17.01 41 16900 28526 46640595
Off label use 25.68 17.01 63 16878 379778 46289343
Neutropenia 25.54 17.01 10 16931 143194 46525927
Parkinson's disease 25.37 17.01 12 16929 1527 46667594
Dermatitis contact 25.18 17.01 22 16919 8101 46661020
Toxicity to various agents 25.00 17.01 24 16917 211742 46457379
Senile dementia 24.95 17.01 7 16934 196 46668925
Headache 24.67 17.01 90 16851 478262 46190859
Psychotic symptom 24.44 17.01 10 16931 900 46668221
Febrile neutropenia 24.05 17.01 3 16938 94624 46574497
Infusion related reaction 23.89 17.01 4 16937 101204 46567917
Apparent death 23.72 17.01 11 16930 1339 46667782
Resting tremor 23.62 17.01 9 16932 671 46668450
Parkinsonism 23.59 17.01 21 16920 7927 46661194
Swelling 23.37 17.01 8 16933 124503 46544618
Product administered at inappropriate site 23.10 17.01 13 16928 2370 46666751
Weight decreased 23.08 17.01 143 16798 210706 46458415
Myalgia 22.95 17.01 8 16933 123080 46546041
Cough 22.91 17.01 30 16911 230219 46438902
Application site vesicles 22.87 17.01 11 16930 1453 46667668
Balance disorder 22.82 17.01 63 16878 64458 46604663
Product prescribing error 22.70 17.01 32 16909 20015 46649106
Hip fracture 22.44 17.01 37 16904 26519 46642602
Agnosia 22.35 17.01 6 16935 142 46668979
Drug ineffective 22.06 17.01 150 16791 677688 45991433
Vascular dementia 21.69 17.01 8 16933 545 46668576
Urinary retention 21.60 17.01 36 16905 26025 46643096
Paraesthesia 21.27 17.01 8 16933 117429 46551692
Abnormal dreams 20.78 17.01 22 16919 10257 46658864
Hyperkinesia 20.65 17.01 11 16930 1801 46667320
Faecaloma 20.11 17.01 19 16922 7733 46661388
Psychotic disorder 19.76 17.01 32 16909 22589 46646532
Medication error 19.61 17.01 38 16903 30873 46638248
Platelet count decreased 19.52 17.01 6 16935 100018 46569103
Depressed level of consciousness 19.42 17.01 49 16892 47520 46621601
Apathy 19.22 17.01 18 16923 7250 46661871
Neuropathy peripheral 18.57 17.01 5 16936 90888 46578233
Paranoia 18.51 17.01 21 16920 10576 46658545
Incorrect product administration duration 18.49 17.01 20 16921 9557 46659564
Mobility decreased 18.37 17.01 56 16885 60538 46608583
Arthritis 18.37 17.01 3 16938 77313 46591808
Unresponsive to stimuli 17.37 17.01 37 16904 32137 46636984
Oropharyngeal pain 17.35 17.01 3 16938 74165 46594956
Pyrexia 17.06 17.01 67 16874 348735 46320386

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 416.96 17.04 271 14095 48788 29889324
Product adhesion issue 401.82 17.04 101 14265 1364 29936748
Confusional state 270.05 17.04 327 14039 134507 29803605
Aggression 258.43 17.04 181 14185 36726 29901386
Application site erythema 251.12 17.04 77 14289 2226 29935886
Dementia 225.54 17.04 113 14253 12348 29925764
Fall 201.09 17.04 332 14034 181540 29756572
Application site pruritus 162.56 17.04 49 14317 1334 29936778
Abnormal behaviour 159.32 17.04 117 14249 25506 29912606
Agitation 139.73 17.04 150 14216 53923 29884189
Cognitive disorder 120.48 17.04 96 14270 23594 29914518
Death 110.57 17.04 398 13968 356885 29581227
Gait disturbance 106.76 17.04 154 14212 74623 29863489
Stoma site discharge 105.60 17.04 36 14330 1465 29936647
Hallucination, visual 103.33 17.04 75 14291 16038 29922074
On and off phenomenon 102.70 17.04 42 14324 2849 29935263
Application site rash 100.13 17.04 30 14336 799 29937313
Freezing phenomenon 96.65 17.04 36 14330 1900 29936212
Somnolence 91.19 17.04 165 14201 96598 29841514
Bradykinesia 85.19 17.04 38 14328 3192 29934920
Blood cholinesterase decreased 83.37 17.04 18 14348 117 29937995
Pneumonia aspiration 79.07 17.04 94 14272 37686 29900426
Disorientation 79.03 17.04 86 14280 31332 29906780
Akinesia 74.33 17.04 32 14334 2468 29935644
General physical health deterioration 72.89 17.04 153 14213 99791 29838321
Muscle rigidity 66.31 17.04 48 14318 10213 29927899
Stoma site erythema 65.54 17.04 23 14343 1021 29937091
Memory impairment 64.18 17.04 84 14282 37090 29901022
Dyskinesia 62.42 17.04 64 14302 21770 29916342
Restlessness 62.37 17.04 65 14301 22534 29915578
Dementia with Lewy bodies 61.55 17.04 19 14347 561 29937551
Delusion 53.39 17.04 45 14321 11944 29926168
Mobility decreased 53.24 17.04 64 14302 25935 29912177
Delirium 52.60 17.04 80 14286 40551 29897561
Device dislocation 50.59 17.04 31 14335 5000 29933112
Gait inability 49.86 17.04 53 14313 18788 29919324
Application site irritation 49.66 17.04 17 14349 700 29937412
Stoma site inflammation 48.23 17.04 16 14350 598 29937514
Parkinson's disease 47.72 17.04 21 14345 1707 29936405
Arthralgia 44.94 17.04 6 14360 135785 29802327
Paranoia 44.87 17.04 38 14328 10150 29927962
Prescribed underdose 42.77 17.04 33 14333 7726 29930386
Dysphagia 42.67 17.04 88 14278 56610 29881502
Fibroma 41.04 17.04 12 14354 293 29937819
Hyperkinesia 40.81 17.04 20 14346 2078 29936034
Sinus bradycardia 40.35 17.04 38 14328 11657 29926455
Speech disorder 40.15 17.04 54 14312 24458 29913654
Application site discolouration 39.93 17.04 11 14355 215 29937897
Tremor 39.08 17.04 101 14265 75262 29862850
Syncope 38.22 17.04 108 14258 84795 29853317
Neutropenia 37.42 17.04 8 14358 128532 29809580
Febrile neutropenia 37.06 17.04 4 14362 106689 29831423
Bradycardia 36.24 17.04 90 14276 65436 29872676
Hangover 36.04 17.04 15 14351 1063 29937049
Application site hypersensitivity 35.75 17.04 9 14357 122 29937990
Product administration error 35.51 17.04 39 14327 14338 29923774
Condition aggravated 35.20 17.04 145 14221 137721 29800391
Marasmus 34.04 17.04 12 14354 540 29937572
Mini mental status examination abnormal 33.98 17.04 6 14360 10 29938102
Stoma site reaction 33.93 17.04 10 14356 251 29937861
Dementia Alzheimer's type 32.44 17.04 11 14355 440 29937672
Therapeutic product effect variable 32.39 17.04 15 14351 1374 29936738
Motor dysfunction 32.31 17.04 25 14341 5877 29932235
Urinary incontinence 31.92 17.04 40 14326 16900 29921212
Parkinsonism 31.77 17.04 27 14339 7242 29930870
Nonspecific reaction 30.13 17.04 14 14352 1292 29936820
Reduced facial expression 30.00 17.04 12 14354 768 29937344
Malaise 29.67 17.04 158 14208 166804 29771308
Psychotic disorder 28.73 17.04 43 14323 21472 29916640
Application site reaction 28.71 17.04 10 14356 434 29937678
Hypokinesia 27.78 17.04 25 14341 7235 29930877
Pancytopenia 27.55 17.04 4 14362 85048 29853064
Sleep disorder 27.24 17.04 45 14321 24434 29913678
Dyspnoea 26.85 17.04 77 14289 333218 29604894
Urinary tract infection 26.83 17.04 87 14279 73572 29864540
Screaming 26.82 17.04 13 14353 1318 29936794
Dysstasia 26.81 17.04 29 14337 10476 29927636
Acute kidney injury 26.12 17.04 58 14308 273784 29664328
Application site vesicles 25.89 17.04 10 14356 583 29937529
Abnormal dreams 25.41 17.04 25 14341 8090 29930022
Drug dispensed to wrong patient 24.80 17.04 7 14359 150 29937962
Incorrect product administration duration 24.54 17.04 18 14348 3904 29934208
Miosis 24.43 17.04 24 14342 7752 29930360
Balance disorder 24.39 17.04 54 14312 36439 29901673
Neuroleptic malignant syndrome 23.83 17.04 34 14332 16261 29921851
Product administration interrupted 23.46 17.04 6 14360 87 29938025
Intentional medical device removal by patient 23.43 17.04 8 14358 327 29937785
Hypersomnia 23.39 17.04 28 14338 11288 29926824
Salivary hypersecretion 23.11 17.04 23 14343 7543 29930569
Apathy 22.94 17.04 21 14345 6211 29931901
White blood cell count decreased 22.88 17.04 6 14360 83941 29854171
Orthostatic hypotension 22.65 17.04 41 14325 23938 29914174
Myalgia 21.83 17.04 5 14361 76662 29861450
Concomitant disease progression 21.51 17.04 14 14352 2506 29935606
Skin irritation 21.31 17.04 17 14349 4175 29933937
Oesophageal dilatation 20.90 17.04 6 14360 137 29937975
Parkinsonian gait 20.77 17.04 8 14358 463 29937649
Wrong technique in product usage process 20.70 17.04 46 14320 31109 29907003
Pain 20.47 17.04 32 14334 172609 29765503
Platelet count decreased 20.21 17.04 13 14353 106116 29831996
Urinary retention 20.09 17.04 47 14319 32870 29905242
Lack of application site rotation 19.93 17.04 3 14363 0 29938112
Loss of consciousness 19.83 17.04 83 14283 79292 29858820
Stoma site hypergranulation 19.44 17.04 7 14359 335 29937777
Stoma site odour 18.64 17.04 5 14361 88 29938024
Stoma site infection 18.30 17.04 9 14357 942 29937170
Psychomotor hyperactivity 18.07 17.04 21 14345 8203 29929909
Aphasia 18.05 17.04 33 14333 19406 29918706
Completed suicide 17.86 17.04 13 14353 99479 29838633
Pleurothotonus 17.68 17.04 9 14357 1014 29937098
Stoma site pain 17.51 17.04 8 14358 710 29937402
Application site inflammation 17.51 17.04 5 14361 112 29938000
Amnesia 17.40 17.04 37 14329 24284 29913828
Toxicity to various agents 17.30 17.04 37 14329 177146 29760966
Cough 17.18 17.04 21 14345 125621 29812491

Pharmacologic Action:

SourceCodeDescription
ATC N06DA03 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
FDA MoA N0000000177 Cholinesterase Inhibitors
FDA EPC N0000175723 Cholinesterase Inhibitor
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D002800 Cholinesterase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018696 Neuroprotective Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:37733 bche inhibitor
CHEBI has role CHEBI:38323 cholinergic drugs
CHEBI has role CHEBI:63726 neuroprotective agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Alzheimer's disease indication 26929004 DOID:10652
Dementia associated with Parkinson's Disease indication 425390006
Diffuse Lewy body disease off-label use 80098002
Moderate to Severe Alzheimer's Type Dementia off-label use
Urinary tract obstruction contraindication 7163005 DOID:5200
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Parkinsonism contraindication 32798002
Sick sinus syndrome contraindication 36083008 DOID:13884
Gastrointestinal ulcer contraindication 40845000
Conduction disorder of the heart contraindication 44808001
Neuromuscular block, function contraindication 55394004
Anorexia nervosa contraindication 56882008 DOID:8689
Diarrhea contraindication 62315008
Gastrointestinal hemorrhage contraindication 74474003
Extrapyramidal disease contraindication 76349003
Weight loss contraindication 89362005
Seizure disorder contraindication 128613002
Asthma contraindication 195967001 DOID:2841
Atrioventricular block contraindication 233917008 DOID:0050820
Vomiting contraindication 422400008
Nausea contraindication 422587007

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.32 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cholinesterase Enzyme INHIBITOR IC50 7.52 CHEMBL IUPHAR
Acetylcholinesterase Enzyme INHIBITOR IC50 7.43 CHEMBL IUPHAR
Acetylcholinesterase Enzyme IC50 5.74 CHEMBL
Acetylcholinesterase Enzyme IC50 5.95 CHEMBL
Butyrylcholinesterase; Protein Bche Enzyme IC50 6.46 CHEMBL
Cholinesterase Enzyme IC50 5.80 CHEMBL
Cholinesterase Enzyme IC50 6.08 CHEMBL
Acetylcholinesterase Enzyme IC50 6.21 CHEMBL
Butyrylcholinesterase Enzyme IC50 6.80 CHEMBL
Acetylcholinesterase Enzyme IC50 5.38 CHEMBL

External reference:

IDSource
4021219 VUID
N0000148665 NUI
D03822 KEGG_DRUG
129101-54-8 SECONDARY_CAS_RN
4021219 VANDF
4021220 VANDF
C0730987 UMLSCUI
CHEBI:64358 CHEBI
CHEMBL636 ChEMBL_ID
CHEMBL215645 ChEMBL_ID
D000068836 MESH_DESCRIPTOR_UI
5077 PUBCHEM_CID
6602 IUPHAR_LIGAND_ID
7562 INN_ID
DB00989 DRUGBANK_ID
PKI06M3IW0 UNII
183379 RXNORM
174208 MMSL
23978 MMSL
31947 MMSL
79573 MMSL
8887 MMSL
d04537 MMSL
007559 NDDF
007560 NDDF
126131008 SNOMEDCT_US
323368009 SNOMEDCT_US
395868008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Exelon HUMAN PRESCRIPTION DRUG LABEL 1 0078-0501 PATCH, EXTENDED RELEASE 4.60 mg TRANSDERMAL NDA 30 sections
Exelon HUMAN PRESCRIPTION DRUG LABEL 1 0078-0502 PATCH, EXTENDED RELEASE 9.50 mg TRANSDERMAL NDA 30 sections
Exelon HUMAN PRESCRIPTION DRUG LABEL 1 0078-0503 PATCH, EXTENDED RELEASE 13.30 mg TRANSDERMAL NDA 30 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 0378-9070 PATCH 4.60 mg TRANSDERMAL ANDA 27 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 0378-9071 PATCH 9.50 mg TRANSDERMAL ANDA 27 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 0378-9072 PATCH 13.30 mg TRANSDERMAL ANDA 27 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 0781-7304 PATCH, EXTENDED RELEASE 4.60 mg TRANSDERMAL NDA authorized generic 27 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 0781-7309 PATCH, EXTENDED RELEASE 9.50 mg TRANSDERMAL NDA authorized generic 27 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 0781-7313 PATCH, EXTENDED RELEASE 13.30 mg TRANSDERMAL NDA authorized generic 27 sections
Rivastigmine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6587 CAPSULE 1.50 mg ORAL ANDA 24 sections
Rivastigmine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0904-7107 CAPSULE 1.50 mg ORAL ANDA 25 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 16714-115 PATCH, EXTENDED RELEASE 4.60 mg TRANSDERMAL ANDA 25 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 16714-116 PATCH, EXTENDED RELEASE 9.50 mg TRANSDERMAL ANDA 25 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 16714-117 PATCH, EXTENDED RELEASE 13.30 mg TRANSDERMAL ANDA 25 sections
Exelon HUMAN PRESCRIPTION DRUG LABEL 1 21695-357 PATCH, EXTENDED RELEASE 4.60 mg TRANSDERMAL NDA 16 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 27241-090 CAPSULE 1.50 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 27241-091 CAPSULE 3 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 27241-092 CAPSULE 4.50 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 27241-093 CAPSULE 6 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 33342-089 CAPSULE 1.50 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 33342-090 CAPSULE 3 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 33342-091 CAPSULE 4.50 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 33342-092 CAPSULE 6 mg ORAL ANDA 25 sections
Rivastigmine Tartrate Human Prescription Drug Label 1 46708-063 CAPSULE 1.50 mg ORAL ANDA 26 sections
Rivastigmine Tartrate Human Prescription Drug Label 1 46708-064 CAPSULE 3 mg ORAL ANDA 26 sections
Rivastigmine Tartrate Human Prescription Drug Label 1 46708-065 CAPSULE 4.50 mg ORAL ANDA 26 sections
Rivastigmine Tartrate Human Prescription Drug Label 1 46708-066 CAPSULE 6 mg ORAL ANDA 26 sections
Rivastigmine Transdermal System HUMAN PRESCRIPTION DRUG LABEL 1 47781-304 PATCH, EXTENDED RELEASE 4.60 mg TRANSDERMAL ANDA 26 sections
Rivastigmine Transdermal System HUMAN PRESCRIPTION DRUG LABEL 1 47781-305 PATCH, EXTENDED RELEASE 9.50 mg TRANSDERMAL ANDA 26 sections
Rivastigmine Transdermal System HUMAN PRESCRIPTION DRUG LABEL 1 47781-405 PATCH, EXTENDED RELEASE 13.30 mg TRANSDERMAL ANDA 26 sections